Central role of the MAPK pathway in Ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 1, 1999, Pages 73-82

  Xi, Xiao Ping ^a   Graf, Kristof ^a,b   Goetze, Stephan ^a,b   Fleck, Eckart ^b   Hsueh, Willa A ^a   Law, Ronald E ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin II; DNA synthesis; Migration; Mitogen activated protein kinase; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; CELL MIGRATION; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; HORMONAL REGULATION; NONHUMAN; ONCOGENE C FOS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0032920339     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.1.73     Document Type: Article

References (50)

1. Duff JL, Berk BC. Angiotensin II-mediated signal transduction events in vascular smooth muscle cells: kinases and phosphatases. Blood Press Suppl. 1995;2:55-60.
2. Berk BC, Corson MA. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res. 1997;80:607-617.
3. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1991;351:233-236.
4. Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin-II type-1 receptor. Nature. 1991; 351:230-233.
5. Molloy CJ, Taylor DS, Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J Biol Chem. 1993;268:7338-7345.
6. Duff JL, Berk BC, Corson MA. Angiotensin II stimulates the pp44 and pp42 mitogen-activated protein kinases in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1992;188:257-264.
7. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathway. J Mol Med. 1996;74:589-607.
8. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1996;270:16483-16486.
9. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem. 1993;268:14553-14556.
10. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897-1905.
11. Graf K, Xi XP, Yang D, Fleck E, Hsueh WA, Law RE. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 1997; 29:334-339.
12. Pang L, Sawada T, Decker S, Saltiel A. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem. 1995;270:13585-13588.
13. Dudley D, Pang L, Decker S, Bridges A, Saltiel A. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995;92:7686-7689.
14. Chamley-Campbell J, Campbell G, Ross R. The smooth muscle cell in culture. Physiol Rev. 1979;59:1-61.
15. Sale E, Atkinson P, Sale G. The requirement of MAP kinase for the differentiation of fibroblasts to adipocytes, for insulin activation of p90 S6 kinase and for insulin or serum stimulation of DNA synthesis. EMBO J. 1995;14:674-684.
16. Glennon P, Kaddoura S, Sale E, Sale G, Fuller S, Sugden P. Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylepinephrine-induced hypertrophic response in rat cardiac myocyte. Circ Res. 1996;78:954-961.
17. Chomczynski PS, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1989;162:156-159.
18. Harpold M, Evans R, Saldit-Georgieff M, Darnell J. Production of mRNA in Chinese hamster cells: relationship of the rate of synthesis to the cytoplasmic concentration of nine specific mRNA sequences. Cell. 1979; 17:1025-1035.
19. Inoue H, Hayase Y, Iwai S, Ohtsuka E. Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and Rnase H. FEBS Lett. 1987;215:327-330.
20. Lazar D, Wiese R, Brady M, Mastick C, Waters S, Yamauchi K, Pessin J, Cuatrecasas P, Saltiel A. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem. 1995;270:20801-20807.
21. Wilkie N, Morton C, Ng LL, Boarder MR. Stimulated mitogen-activated protein kinase is necessary but not sufficient for the mitogenic response to angiotensin II. J Biol Chem. 1996;271:32447-32453.
22. Lu G, Meier KE, Jaffa AA, Rosenzweig SA, Egan BM. Oleic acid and angiotensin II induce a synergistic mitogenic response in vascular smooth muscle cells. Hypertension. 1998;31:978-985.
23. Pickering JG, Isner JM, Ford CM, Weir L, Lazarovits A, Rocnik EF, Chow LH. Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Circulation. 1996;93:772-780.
24. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, Cobb MH, Shaw PE. ERK phosphorylation potentiates ELK-1-mediated ternary complex formation and transactivation. EMBO J. 1995;14:951-962.
25. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE. Direct stimulation of JAK/STAT pathway by the angiotensin II AT-1 receptor. Nature. 1995;375:247-250.
26. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR. Protein kinase C activates RAF-1 by direct phosphorylation. Nature. 1994;364:249-252.
27. Bhat GJ, Thekkumkara TJ, Thomas WG, Conrad KM, Baker KM. Angiotensin II stimulates sis-inducing factor-like DNA binding activity. J Biol Chem. 1994;269:31443-31449.
28. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stal1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82:241-250.
29. Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH, Spiegelman BM. c-fos is required for malignant progression of skin tumors. Cell. 1995;82:721-732.
30. Marrero MB, Schieffer B, Li B, Sun J, Harp JB, Ling BN. Role of Janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem. 1997;272:24684-24690.
31. Robinson CJM, Scott PH, Allan AB, Jess T, Gould GW, Plevin R. Treatment of vascular smooth muscle cells with antisense phosphorothioate oligodeoxynucleotides directed against p42 and p44 mitogen-activated protein kinases abolishes DNA synthesis in response to platelet-derived growth factor. Biochem J. 1996;320:123-127.
32. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell: role of cyclic-nucleotides and angiotensin 1 receptors. J Clin Invest. 1995;96:141-149.
33. Graves LM, Bornfeldt KE, Raines EW, Potts BC, Macdonald SG, Ross R, Krebs EG. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci U S A. 1993;90:10300-10304.
34. Higaki M, Sakaue H, Ogawa W, Kasuga M, Shimokado K. Phosphatidylinositol 3-kinase-independent signal transduction pathway for platelet-derived growth factor-induced chemotaxis. J Biol Chem. 1996;271: 29342-29346.
35. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol. 1997;137:481-492.
36. Sachinidis A, Weisser P, Ko Y, Schulte K, Meyer KB, Neyses L, Vetter H. Angiotensin II induces formation of the early growth response gene-1 protein in rat vascular smooth muscle cells. FEBS Lett. 1992;313: 109-112.
37. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
38. Leduc I, Haddad P, Giasson E, Meloche S. Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells. Mol Pharmacol. 1995;48:582-592.
39. Arai H, Escobedo JA. Angiotensin II type 1 receptor signals through raf-1 by a protein kinase C-dependent, Ras-independent mechanism. Mol Pharmacol. 1996;50:522-528.
40. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
41. van Kleef EM, Fingerle J, Daemen MJ. Angiotensin II-induced progression of neointimal thickening in the balloon-injured rat carotid artery is AT1 receptor mediated. Arterioscler Thromb Vasc Biol. 1996;16: 857-863.
42. deBlois D, Viswanathan M, Su JE, Clowes AW, Saavedra JM, Schwartz SM. Smooth muscle DNA replication in response to angiotensin II is regulated differently in the neointima and media at different times after balloon injury in the rat carotid artery: role of AT1 receptor expression. Arterioscler Thromb Vasc Biol. 1996;16:1130-1137.
43. Prescott MF, Webb RL, Reidy MA. Angiotensin-converting enzyme inhibitor versus angiotensin II receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol. 1991;139:1291-1296.
44. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after PTCA? Results of the MERCATOR study: a multicenter, double-blind, placebo-controlled trial. Circulation. 1992;86:100-110.
45. Faxon DP. The Multicenter American Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol. 1995;25:362-369.
46. GISSI-3 Coordinating Center. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343: 1115-1122.
47. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
48. Ferns G, Raines E, Sprugel K, Montani A, Reidy M, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty with an antibody to PDGF. Science. 1991;253:1129-1132.
49. Linder V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res. 1991;68: 106-113.
50. Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. Circulation. 1996;93:848-852.